Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Jessica J. Lin"'
Autor:
Joao V. Alessi, Arielle Elkrief, Biagio Ricciuti, Xinan Wang, Alessio Cortellini, Victor R. Vaz, Giuseppe Lamberti, Rosa L. Frias, Deepti Venkatraman, Claudia A.M. Fulgenzi, Federica Pecci, Gonzalo Recondo, Alessandro Di Federico, Adriana Barrichello, Hyesun Park, Mizuki Nishino, Grace M. Hambelton, Jacklynn V. Egger, Marc Ladanyi, Subba Digumarthy, Bruce E. Johnson, David C. Christiani, Xihong Lin, Justin F. Gainor, Jessica J. Lin, David J. Pinato, Adam J. Schoenfeld, Mark M. Awad
Publikováno v:
Journal of Thoracic Oncology. 18:731-743
Autor:
Jessica J, Lin, Justin F, Gainor
Publikováno v:
The Lancet Respiratory Medicine. 11:302-304
Publikováno v:
Journal of Thoracic Oncology. 18:e13-e14
Publikováno v:
Nature
Lung cancer is one of the most aggressive tumors. Targeted therapies stratified by oncogenic drivers has remarkably improved therapeutic outcomes in patients with non-small cell lung cancer (NSCLC) (1). However, such oncogenic drivers are not found i
Autor:
Alice T. Shaw, Jochen K. Lennerz, Rebecca S. Heist, Justin F. Gainor, Kelly Goodwin, Andrew Do, Philicia Moonsamy, Ibiayi Dagogo-Jack, Aaron N. Hata, Subba R. Digumarthy, Inga T. Lennes, Zofia Piotrowska, Kristin Price, Sara Stevens, Alona Muzikansky, Jessica J. Lin, Lecia V. Sequist
Publikováno v:
Journal of Thoracic Oncology. 16:850-859
Introduction Capmatinib is approved for MET exon 14–altered NSCLC on the basis of activity in targeted therapy–naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor.
Autor:
Geoffrey R. Oxnard, Satoshi Yoda, Bruce G. Robinson, Eliana B. Gomez, Sarah-Jane Dawson, S. Michael Rothenberg, Justin F. Gainor, Dahlia Henry, Oliver Gautschi, Christine Khoo, Stephen Q. Wong, Edward Y. Zhu, Andrew T. Metcalf, Louis Stancato, Brian B. Tuch, Barbara J. Brandhuber, Steve Andrews, Jessica J. Lin, Lavinia Tan, Kevin Ronald Condroski, Vivek Subbiah, Lecia V. Sequist, Wayne Blosser, James F. Blake, Joshua Ballard, Kolakowski Gabrielle R, Kevin Ebata, Alexander Drilon, Benjamin Solomon, Michele Nguyen, Sebastian Hollizeck
Publikováno v:
Journal of Thoracic Oncology. 15:541-549
Introduction Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and R
Autor:
Alissa J. Cooper, Alona Muzikansky, Jochen Lennerz, Farhaana Narinesingh, Mari Mino-Kenudson, Yin P. Hung, Zofia Piotrowska, Ibiayi Dagogo-Jack, Lecia V. Sequist, Justin F. Gainor, Jessica J. Lin, Rebecca S. Heist
Publikováno v:
JTO Clinical and Research Reports. 3:100390
Autor:
Jaime L. Schneider, Alona Muzikansky, Jessica J. Lin, Elizabeth A. Krueger, Inga T. Lennes, Joseph O. Jacobson, Michael Cheng, Rebecca S. Heist, Zofia Piotrowska, Justin F. Gainor, Alice T. Shaw, Ibiayi Dagogo-Jack
Publikováno v:
JTO Clinical and Research Reports. 3:100347
The central nervous system (CNS) is a common site of progression among patients withPatients with metastaticA total of 16 patients were enrolled between November 2016 and January 2019. Nine patients (56%) had received prior CNS radiation, with a medi
Autor:
Alice T. Shaw, Jochen K. Lennerz, Jessica J. Lin, Rebecca J. Nagy, Justin F. Gainor, Lorin A. Ferris, Marguerite Rooney, Richard B. Lanman, Ibiayi Dagogo-Jack, Jennifer Ackil, Emily Chin
Publikováno v:
Journal of Thoracic Oncology. 14:816-824
Introduction Circulating tumor DNA analysis is an emerging genotyping strategy that can identify tumor-specific genetic alterations in plasma including mutations and rearrangements. Detection of ROS1 fusions in plasma requires genotyping approaches t
Autor:
Justin F. Gainor, Ginger Y. Jiang, Jennifer Ackil, Alice T. Shaw, Beow Y. Yeap, Subba R. Digumarthy, Jessica J. Lin, Nencyben Joshipura, Sandra Rincon
Publikováno v:
Journal of Thoracic Oncology. 14:683-690
Background Central nervous system (CNS) metastases represent a significant source of morbidity and mortality for patients with ALK tyrosine kinase gene (ALK)-positive NSCLC. Alectinib has demonstrated robust CNS activity in both crizotinib-naive and